Peripheral Artery Disease News and Research

RSS

Peripheral arterial disease (PAD) occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain for patients, limited physical mobility, and life-threatening non-healing leg ulcers. According to the American Heart Association, this condition affects approximately 8 to 12 million Americans. With only about 25 percent of PAD patients undergoing treatment, it is a disease that is largely under-diagnosed and under-treated. If left untreated, PAD can lead to critical leg ischemia, a condition where not enough blood is being delivered to the leg to keep the tissue alive. Total loss of circulation to the legs and feet can cause gangrene and lead to amputation.

Pall applies patent with USPTO for disposable, closed cell collection and seeding system

Pall Corporation, a global leader in filtration, separation and purification, has applied for a patent with the United States Patent and Trademark Office (USPTO) for a disposable, closed cell collection and seeding system that is being developed for use in ground-breaking vein regeneration procedures.

From Pall Corporation 23 Nov 2011

NYU Langone cardiovascular experts present new research findings at AHA 2011

Experts from the Cardiac & Vascular Institute at NYU Langone Medical Center presented new research findings at the American Heart Association Scientific Sessions 2011 held November 12-16, 2011 in Orlando, Florida.

18 Nov 2011

Supervised exercise more effective than stenting or medication for PAD

Supervised exercise was shown to be more effective than stenting or medication for improved walking ability in patients with peripheral artery disease. The findings from a national study were reported today at the 2011 American Heart Association Scientific Sessions meeting.

17 Nov 2011

Risk of heart failure appears to be higher among low-income seniors

The risk of heart failure appears to be higher among low-income seniors — even those with a college education — according to research from the University of Alabama at Birmingham presented during the 2011 American Heart Association Scientific Sessions.

15 Nov 2011

FDA approves Medtronic's Assurant Cobalt stent to treat narrowed iliac arteries

Advancing the treatment of peripheral artery disease, Medtronic, Inc. today announced approval by the U.S. Food and Drug Administration (FDA) of the Assurant Cobalt Iliac Balloon-Expandable Stent System.

From Medtronic 1 Nov 2011

FDA's Circulatory System Devices Panel unanimously recommends Cook Medical's Zilver PTX Drug-Eluting Stent

The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.

14 Oct 2011

Engager Transcatheter Aortic Valve Implantation System pivotal trial to be conducted at 11 European centers

Medtronic, Inc. today announced the start of the Engager European Pivotal Trial to pursue CE Mark for the Engager Transcatheter Aortic Valve Implantation System in patients suffering from severe aortic stenosis.

From Medtronic 28 Sep 2011

Boston Scientific introduces Coyote Balloon Catheter for peripheral angioplasty

Boston Scientific Corporation has launched its Coyote Balloon Catheter, a highly deliverable and ultra-low profile 0.014 inch balloon dilatation catheter designed to treat patients undergoing peripheral angioplasty procedures below the knee. The Company has begun marketing the product in the U.S., Europe and other international markets.

19 Sep 2011

Patients with coronary artery disease more likely to have complications from orthopedic surgery

Thrombotic and bleeding events are complications that may occur after surgery. With the aging population in the western world, there are more patients undergoing orthopedic surgery than ever before. This makes understanding the risk of complications from orthopedic surgery exceedingly important. However, there is a lack of data investigating the incidence of thrombotic and bleeding complications in orthopedic surgery.

31 Aug 2011

Specific inhibitor of microRNA-100 can stimulate development of new blood vessels

A specific inhibitor of the small regulatory RNA-molecule "microRNA-100" can be used to stimulate the growth of new blood vessels, if a major artery is chronically occluded.

29 Aug 2011

New ESC Guidelines on diagnosis and treatment of peripheral artery disease

For cardiologists, coronary artery disease is the most important presentation of atherosclerosis. Patients with coronary artery disease may also have symptomatic or asymptomatic atherosclerosis in other vascular areas (peripheral artery disease).

26 Aug 2011

FDA approves Abbott's RX Herculink Elite Renal Stent System for renal artery stenosis

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplying blood to the kidneys) in patients with uncontrolled hypertension (high blood pressure).

10 Aug 2011

Scientists confirm feasibility of new battery-powered skin patch drug delivery system

Scientists have confirmed the feasibility of using a new drug delivery system - the basis for a battery-powered skin patch - to administer medication that shows promise for treating peripheral artery disease (PAD) and healing stubborn skin ulcers and burns.

5 Aug 2011

USPTO issues notice of allowance for Vermillion's PAD biomarker patent

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent entitled "Beta-2 microglobulin as a Biomarker for Peripheral Artery Disease."

3 Aug 2011

RegenoCELL to open new facility in Panama for treatment of congestive heart failure

RegenoCELL Therapeutics, Inc., a leader in adult stem cell therapy, is pleased to announce it is planning to open another state of the art facility in Panama for patients to be treated for congestive heart failure and peripheral artery disease with its autologous stem cell therapy.

30 Jul 2011

BioMedix receives U.S. patent titled, 'System and Method for Testing for Cardiovascular Disease'

BioMedix, a leader in providing integrated Health Information Technology (HIT) products and services, has been awarded a U.S. Patent recognizing its innovative solutions and methods for detecting and managing cardiovascular disease.

22 Jul 2011

Series of articles explore recent evidence-based vascular medicine

As the population ages and obesity and diabetes increase, more people suffer from noncardiac vascular diseases. In the July/August issue of Progress in Cardiovascular Diseases, published by Elsevier, a series of articles from recognized experts on key topics in vascular disease and endovascular medicine provide an insightful compendium of the evidence available to help improve the care of this complex patient population.

20 Jul 2011

NSVascular signs exclusive license with UCLA for Thin-Film Nitinol technology

NeuroSigma, Inc., a Los Angeles-based medical device company, today announced the formation of a majority owned subsidiary, NSVascular, Inc. and the signing of an exclusive license with the University of California, Los Angeles (UCLA) covering its medical applications of Thin-Film Nitinol (TFN) technology. Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat.

18 Jul 2011

Genetic biomarker may help identify patients at increased risk of bypass surgery

Outcomes of bypass surgery to repair blocked arteries in the legs tend to be better in the roughly one-in-five people who have inherited a specific genetic variation from both parents, according to a study presented at the late-breaking clinical trials session of the Vascular Annual Meeting in Chicago on June 18, 2011.

20 Jun 2011

Boston Scientific to launch Mustang PTA Balloon Catheter worldwide

Boston Scientific Corporation today announced the global launch of its Mustang™ PTA Balloon Catheter, a highly deliverable 0.035 inch percutaneous transluminal angioplasty (PTA) catheter designed for a wide range of peripheral angioplasty procedures. The Company plans to launch the product immediately in the U.S., Europe and other international markets.